• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

abbott

The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions

June 8, 2022 By Sean Whooley

American Diabetes Association Abbott FreeStyle Libre 3 Dexcom G7 Insulet Omnipod 5 Medtronic MiniMed 780G

For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, American Diabetes Association, Bigfoot Biomedical, dariohealth, Dexcom, Insulet, Medtronic, One Drop, Tandem Diabetes Care, Virta Health

Late-breaking data supports Abbott FreeStyle Libre 3 in 14-day glucose monitoring

June 6, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE:ABT) announced data demonstrating the accuracy of its next-generation FreeStyle Libre 3 continuous glucose monitor (CGM). The latest version of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world at the size of just two stacked U.S. pennies — picked up FDA clearance for people with […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, American Diabetes Association

Abbott to develop biowearable for continuous monitoring of glucose, ketone levels

June 3, 2022 By Sean Whooley

Abbott logo updated

Abbott (NYSE:ABT) announced today that it is developing a new biowearable for continuously monitoring both glucose and ketone levels. The all-in-one sensor has already garnered FDA breakthrough device designation and will be used in pivotal trials in 2023, with regulatory submissions to follow thereafter. Abbott Park, Illinois-based Abbott said in a news release that the […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pediatrics, Regulatory/Compliance Tagged With: abbott

FDA clears Abbott’s next-gen FreeStyle Libre 3 14-day CGM

May 31, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE:ABT) announced today that it received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor. FDA clearance for the latest iteration of the company’s FreeStyle Libre platform — designed as the smallest and thinnest CGM sensor in the world — covers use by people 4 years of age and older living with […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: abbott, FDA

Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes

May 12, 2022 By Sean Whooley

Abbott Xience Skypoint

Abbott (NYSE:ABT) announced today that its Xience Skypoint drug-eluting stent platform is now available globally. Xience Skypoint has received FDA approval, the CE mark, and PMDA approval in Japan for the broadest expansion with the availability of extended sizes of 4.5 mm and 5 mm offerings. According to Abbott, Xience Skypoint stents are now the […]

Filed Under: Auto-injectors, Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: abbott

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

May 3, 2022 By Sean Whooley

ATTD 2022 diabetes tech

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, Ascensia Diabetes Care, Beta Bionics, CamDiab, dariohealth, Dexcom, Diabeloop, Insulet, Medtronic, One Drop, Tandem Diabetes Care, Walmart, welldoc, Ypsomed

Analysis backs use of Abbott’s FreeStyle Libre CGM in type 1, type 2 diabetes

April 28, 2022 By Sean Whooley

Abbott FreeStyle Libre CGM

Abbott (NYSE:ABT) announced today that a new real-world meta-analysis provided positive data for its FreeStyle Libre system. The analysis of 75 real-world observational studies of the FreeStyle Libre continuous glucose monitoring (CGM) system demonstrated significant reductions in glycated hemoglobin (HbA1c) sustained for up to 24 months in adults with both type 1 and type 2 […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott

Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery

April 27, 2022 By Sean Whooley

Abbott FreeStyle Libre 3 CamDiab Ypsomed ypsopump

Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system. The companies announced the partnership at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. It seeks to develop and commercialize the integrated AID system with an initial focus centered around […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, CamDiab, Ypsomed

Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom

March 30, 2022 By Sean Whooley

Abbott FreeStyle Libre Dexcom G6

Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS), CGM, Dexcom, Reimbursement

Japan approves expanded reimbursement coverage for Abbott’s FreeStyle Libre CGM

March 24, 2022 By Sean Whooley

Abbott FreeStyle Libre CGM

Abbott (NYSE:ABT) announced today that it received expanded reimbursement coverage in Japan for the FreeStyle Libre system. Japan’s Ministry of Health, Labour and Welfare approved the expansion for the continuous glucose monitoring (CGM) system to include all people with diabetes who use insulin at least once per day. Abbott Park, Illinois-based Abbott said the expanded […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance Tagged With: abbott, Reimbursement

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 10
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS